Neratinib in Early-Stage HER2-Positive Breast Cancer

被引：1
|
作者：
Cherian, Mathew A.
Ma, Cynthia X.
机构：
来源：
BREAST DISEASES | 2015年 / 26卷 / 04期
关键词：
D O I：
10.1016/j.breastdis.2015.10.040
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
[No abstract available]
引用
收藏
页码：285 / 287
页数：4
相关论文
共 50 条
  • [41] A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.
    Adam-Artigues, Anna
    Angel Beltran, Miguel
    Antonio Carbonell-Asins, Juan
    Zuniga, Sheila
    Moragon, Santiago
    Martinez, Maite
    Hernando, Cristina
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Lluch, Ana
    Bermejo, Begona
    Eroles, Pilar
    Miguel Cejalvo, Juan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Matters Arising: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
    Ahmed M. Alaa
    Adrian L. Harris
    Mihaela van der Schaar
    [J]. npj Breast Cancer, 9
  • [43] Trastuzumab - A review of its use in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, GL
    Keam, SJ
    [J]. DRUGS, 2006, 66 (04) : 449 - 475
  • [44] Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks Problem
    Drago, Joshua Z.
    Jhaveri, Komal
    [J]. JCO ONCOLOGY PRACTICE, 2021, 17 (06) : 334 - +
  • [45] Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
    Sardesai, Sagar D.
    Kassem, Mahmoud
    Morgan, Evan
    Palettas, Marilly
    Stephens, Julie
    Williams, Nicole Olivia
    Stover, Daniel G.
    Van Deusen, Jeffery
    Wesolowski, Robert
    Lustberg, Maryam B.
    Ramaswamy, Bhuvaneswari
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer
    Mathew, Aju
    Brufsky, Adam
    [J]. LANCET ONCOLOGY, 2017, 18 (04): : 428 - 429
  • [47] TrastuzumabA Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    [J]. Drugs, 2006, 66 : 449 - 475
  • [48] Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer
    Down, Sue K.
    Lucas, Olivia
    Benson, John R.
    Wishart, Gordon C.
    [J]. ONCOLOGY LETTERS, 2014, 8 (06) : 2757 - 2761
  • [49] Src inhibition overcomes neratinib resistance in HER2-positive breast cancer
    Conlon, Neil
    Lowry, Michelle
    Breslin, Susan
    O'Driscoll, Lorraine
    Eustace, Alexander J.
    Crown, John
    O'Donovan, Norma
    Collins, Denis M.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [50] Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    Huang, Shang-Xiao
    Wang, Han-Lei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 252 - +
12345